CPHI Barcelona 2023
Interview: AB-Biotics keen to connect with pharma partners at CPHI Barcelona
OSP: Is AB-Biotics a regular attendee at CPHI? If so why.
We’ve been attending CPHI for quite some time, but this is the first year we will attend as sponsors. For us, it has always been important to connect with our existing partners, predominantly from the pharma sector, and share our latest innovations and developments with new prospects looking to add to their nutraceutical portfolio, since our biotic solutions are within the food supplements regulatory space. We investigate complex indications such as IBS, Fatty Liver, hypercholesterolemia, or anxiety, so our products can be given as a co-treatment with well-established drugs.
OSP: Are you showcasing anything new?
Our purpose is to constantly innovate within the probiotics space with precision probiotic solutions. This year, we are presenting a probiotic formula that has been clinically tested to balance oestrogen levels during menopause. We will also be showcasing our medical device solutions, which include eye drops developed for dry eye disease (AB-PROTEARS), as well as a postbiotic for weight management LipiGO, shown to prevent the rebound effect. We are also excited to present our synbiotic for antibiotic-associated diarrhea, AB-Digest - a next-generation digestive probiotic that is an ideal co-treatment to antibiotics.
OSP: What do you hope to achieve from this year’s event?
We hope to not only increase our visibility within the space, but to further educate the pharmaceutical sector about the potential of probiotics and the synergies that can be achieved in conjunction with medical devices and well-established drugs. We are very well known within the probiotics industry, and we know that we can be a great partner to pharmaceutical companies that want to add natural, innovative and trending solutions to their portfolio.
OSP: Why people should stop by and see you?
There is still a lot to learn in the probiotics space. We would like invite visitors to come to stand #4129 to further understand the potential of well-studied precision probiotics and how they could appeal to consumers looking to proactively address their health.
